Compare REED & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | CNSP |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.5M |
| IPO Year | 2009 | 2019 |
| Metric | REED | CNSP |
|---|---|---|
| Price | $0.64 | $5.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 142.8K | 2.5K |
| Earning Date | 08-11-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,065,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $1.90 |
| 52 Week High | $5.97 | $10.54 |
| Indicator | REED | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 49.80 |
| Support Level | $0.63 | $5.15 |
| Resistance Level | $0.94 | $5.53 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 45.25 | 74.69 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.